ACP
WHWK

Acuta Capital Partners’s Whitehawk Therapeutics WHWK Stock Holding History

Acuta Capital Partners’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.5M Buy
4,685,912
+1,275,510
+37% +$5.31M 14.96% 2
2026
Q1 		$11.8M Hold
3,410,402
– – 8.3% 3
2025
Q4 		$8.25M Hold
3,410,402
– – 5.6% 5
2025
Q3 		$6.48M Hold
3,410,402
– – 6.7% 4
2025
Q2 		$6.38M Hold
3,410,402
– – 8.9% 3
2025
Q1 		$6.07M Buy
3,410,402
+1,561,000
+84% +$4.08M 7.04% 4
2024
Q4 		$5.83M Hold
1,849,402
– – 5.87% 6
2024
Q3 		$3.81M Hold
1,849,402
– – 3.09% 13
2024
Q2 		$2.7M Hold
1,849,402
– – 2.27% 17
2024
Q1 		$4.33M Hold
1,849,402
– – 2.81% 15
2023
Q4 		$3.74M Hold
1,849,402
– – 2.1% 20
2023
Q3 		$8.95M Hold
1,849,402
– – 6% 3
2023
Q2 		$12.6M Hold
1,849,402
– – 8.57% 2
2023
Q1 		$13.4M Hold
1,849,402
– – 9.86% 2
2022
Q4 		$19.6M Hold
1,849,402
– – 12.08% 1
2022
Q3 		$26.1M Buy
1,849,402
+320,000
+21% +$4.21M 11.25% 2
2022
Q2 		$18.8M Hold
1,529,402
– – 10.5% 2
2022
Q1 		$26M Hold
1,529,402
– – 12.13% 2
2021
Q4 		$36.9M Hold
1,529,402
– – 15.53% 1
2021
Q3 		$44.9M Buy
+1,529,402
New +$46.6M 15.85% 1

Other funds holding WHWK

YF
Yu Fan $108M AUM 137.54% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Acuta Capital Partners's WHWK Position: Q2 2026 in Review

Acuta Capital Partners increased its Whitehawk Therapeutics (WHWK) stake by 37% in Q2 2026, buying an estimated $5.31M and bringing the position to 4,685,912 shares worth $21.5M. The position accounts for 14.96% of the portfolio, ranked #2.

Acuta Capital Partners first reported a position in WHWK in Q3 2021 and has held it in 20 quarters since. The position peaked at $44.9M in Q3 2021. 78 funds tracked by Wall St. Rank hold WHWK as of Q2 2026.

  • Acuta Capital Partners held 4,685,912 shares of Whitehawk Therapeutics worth $21.5M as of Q2 2026.
  • Acuta Capital Partners bought 1,275,510 Whitehawk Therapeutics shares in Q2 2026, an estimated $5.31M.
  • Whitehawk Therapeutics made up 14.96% of Acuta Capital Partners's portfolio in Q2 2026, its #2 holding.
  • Acuta Capital Partners first reported a position in Whitehawk Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Acuta Capital Partners's Whitehawk Therapeutics position peaked at $44.9M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.